港股异动 | 康方生物(09926)午前涨近3% 依沃西联合化疗1L治疗sq-NSCLC上市申请获NMPA受理

智通财经2025-07-29

智通财经APP获悉，康方生物(09926)午前涨近3%，截至发稿，涨2.12%，报153.8港元，成交额9.02亿港元。消息面上，据康方生物官微消息，7月28日，国家药品监督管理局药品审评中心(CDE)官网显示，公司独立自主研发的PD-1/VEGF双特异性抗体依达方®(依沃西单抗注射液)，联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的新药上市许可申请(sNDA)已被受理。PD-1/L1...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555108945?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-29 11:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555108945","market":"sh","top_or_hot":-1,"title":"港股异动 | 康方生物(09926)午前涨近3% 依沃西联合化疗1L治疗sq-NSCLC上市申请获NMPA受理","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，康方生物(09926)午前涨近3%，截至发稿，涨2.12%，报153.8港元，成交额9.02亿港元。消息面上，据康方生物官微消息，7月28日，国家药品监督管理局药品审评中心(CDE)官网显示，公司独立自主研发的PD-1/VEGF双特异性抗体依达方®(依沃西单抗注射液)，联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的新药上市许可申请(sNDA)已被受理。PD-1/L1...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1323000.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康方生物(09926)午前涨近3% 依沃西联合化疗1L治疗sq-NSCLC上市申请获NMPA受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康方生物(09926)午前涨近3% 依沃西联合化疗1L治疗sq-NSCLC上市申请获NMPA受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 11:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1323000.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康方生物(09926)午前涨近3%，截至发稿，涨2.12%，报153.8港元，成交额9.02亿港元。消息面上，据康方生物官微消息，7月28日，国家药品监督管理局药品审评中心(CDE)官网显示，公司独立自主研发的PD-1/VEGF双特异性抗体依达方®(依沃西单抗注射液)，联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的新药上市许可申请(sNDA)已被受理。PD-1/L1...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1323000.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417516571.SGD","symbol_name":"Allianz Oriental Income Cl AT Acc SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1323000.html","article_id":"2555108945","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555108945","pubTimestamp":1753760835,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，据康方生物官微消息，7月28日，国家药品监督管理局药品审评中心官网显示，公司独立自主研发的PD-1/VEGF双特异性抗体依达方，联合化疗一线治疗晚期鳞状非小细胞肺癌的新药上市许可申请已被受理。PD-1/L1抑制剂联合化疗是NSCLC领域当前全球最优SOC，依沃西联合方案有望成为广大sq-NSCLC患者一线治疗的全新选择。据介绍，PD-1联合化疗是免疫抑制剂疗法在全球获得巨大临床突破和商业价值的核心疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK1574":"生物医药B类股","09926":"康方生物","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1720050803.USD":"安联全方位中国股票基金","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC"},"translate_title":"Changes in Hong Kong stocks | Akeso Biotech (09926) rose nearly 3% before noon Ivoxi combined with chemotherapy 1L for the treatment of sq-NSCLC listing application was accepted by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"智通财经APP获悉，康方生物(09926)午前涨近3%，截至发稿，涨2.12%，报153.8港元，成交额9.02亿港元。消息面上，据康方生物官微消息，7月28日，国家药品监督管理局药品审评中心(CDE)官网显示，公司独立自主研发的PD-1/VEGF双特异性抗体依达方®(依沃西单抗注射液)，联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的新药上市许可申请(sNDA)已被受理。PD-1/L1抑制剂联合化疗是NSCLC领域当前全球最优SOC，依沃西联合方案有望成为广大sq-NSCLC患者一线治疗的全新选择。据介绍，PD-1联合化疗是免疫抑制剂疗法在全球获得巨大临床突破和商业价值的核心疗法。此次依沃西新适应症的sNDA，则正是基于依沃西联合化疗“头对头”替雷利珠单抗联合化疗的III期临床(AK112-306/HARMONi-6研究)强阳性结果。继单药头对头帕博利珠单抗之后，战胜PD-1联合化疗，是依沃西方案推动全球肿瘤免疫治疗成功实现更广泛的迭代升级的重要一步，展现了依沃西疗法在全球范围内巨大的临床突破性价值和商业价值。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555108945","isCrawlerRequest":true}